ProCE Banner Activity

Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Slideset Download
Conference Coverage
Venetoclax plus navitoclax (combined with chemotherapy) was well tolerated with promising efficacy in heavily pretreated patients with R/R ALL and LL.

Released: December 09, 2019

Expiration: December 07, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company